"Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results" by Philip Mease

Selected Works of Philip Mease, MD

Follow Contact

Article

Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results

Arthritis & Rheumatism (2019)

Philip Mease, University of Washington

Link

Disciplines

Physical Therapy,
Medicine and Health Sciences and
Immunology and Infectious Disease

Publication Date

February 1, 2019

DOI

10.1002/art.40759

Citation Information

Philip Mease. "Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results" Arthritis & Rheumatism Vol. 71 Iss. 2 (2019) p. 179 - 181
Available at: http://works.bepress.com/philip-mease/309/